FEB 19, 2014 10:00 AM PST
Next-generation sequencing applications in advanced cancer samples: Experience with Ion AmpliSeq custom panels
122 52 2557

Speakers:
  • Medical Director of Knight Diagnostic Laboratories Director of Molecular Pathology, Oregon Health & Science University
    Biography
       
      After undergraduate studies at the Univ. of California, Berkeley, Professor Corless received his MD and PhD degrees from Washington University, St. Louis. He did his residency training in Anatomic Pathology at the Brigham & Women's Hospital, Boston, where he also completed fellowship training in GI Pathology and GU Pathology. In 1994, he joined the faculty of Oregon Health & Science University as an Assistant Professor. He has served as the residency program director in Pathology and medical director of surgical pathology for OHSU Hospital. He is an Associate Director of the Oregon Clinical & Translational Research Institute, and he presently serves as Chief Medical Officer for the OHSU Knight Diagnostic Laboratories. In addition to practicing surgical pathology, Dr. Corless has expertise in the application of molecular diagnostics to the classification and prognostication of solid tumors. He was promoted to Professor of Pathology in 2004 and is an author on over 200 publications.
       

    Abstract:
    Making precision cancer care a future reality requires novel approachesto finding treatment targets in cancers. Single-gene assays currently performed in clinical research laboratories are inadequate in the face of the rapidly growing list of genetic mutations that are potentially actionable. This presentation will focus on our experience in designing and running custom Ion AmpliSeq cancer gene panels on the Ion PGM System, an approach we are using to increase the understanding of genetic mutations in advanced cancers. Consideration will be given to detecting mutations of various types, as well as alterations in gene copy number. Critical pre-analytic factors and the integration of other technologies that define clinically significant targets
    for future treatment will also be discussed.

    Show Resources
    Loading Comments...